May 23, 2013 6:37 PM ET

Biotechnology

Company Overview of Point Therapeutics Inc

Company Overview

As of February 12, 2008, Point Therapeutics Inc. was acquired by Dara BioSciences Inc., in a reverse merger transaction. Point Therapeutics, Inc., a development stage biopharmaceutical company, engages in the development of dipeptidyl peptidase (DPP) inhibitors for use in cancer and type 2 diabetes. Its DPP inhibitors are enzymes that regulate various physiological processes involved in tumor growth and host responses to cancer and type 2 diabetes. The company’s lead product candidate, talabostat is in Phase III a clinical trial for the treatment of metastatic nonsmall cell lung cancer. Point Therapeutics also develops PT-630, a DPP inhibitor and preclinical lead drug candidate, which is use...

Detailed Description

70 Walnut Street

Wellesley Hills, MA 02481

United States

Founded in 1993

Phone:

781-239-7502

Fax:

781-239-8005

Key Executives for Point Therapeutics Inc

Point Therapeutics Inc does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Nimbus Discovery, LLC United States
Cardiovascular Clinical Studies, Inc. United States
Pyxant Labs Inc. United States
Genovics United States
INO Therapeutics LLC United States

Recent Private Companies Transactions

Type
Date		 Target
No transactions available in the past 12 months.
Report Data IssueReport Data Issue
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Point Therapeutics Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.

Close